Appointment dossier — Uterine Carcinosarcoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Uterine Carcinosarcoma
- Carboplatin — Human evidence · 1 positive · PMID 35007153
- Ifosfamide — Human evidence · 1 positive · PMID 35007153
- Paclitaxel — Human evidence · 1 positive · PMID 35007153
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT05619913 · Phase 2 — EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (Australia)
- NCT05902988 · Phase 1 / Phase 2 — A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer (United States)
- NCT05269381 · Phase 1 / Phase 2 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (United States)
- NCT03686124 · Phase 1 / Phase 2 — ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (United States)
- NCT07262619 · Phase 1 / Phase 2 — EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors (United States)
- NCT04657068 · Phase 1 / Phase 2 — A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (United States)
- NCT06730347 · Phase 2 — A Study of Lorigerlimab in Participants With Advanced Solid Tumors (United States)
- NCT05238922 · Phase 1 — Study of INCB123667 in Subjects With Advanced Solid Tumors (United States)
- NCT05799274 · Phase 1 — Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors (United States)
- NCT06508307 · Phase 1 — A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors (China)
- NCT06349642 — Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform (United States)
- NCT02543710 · Phase 4 — Biomarker Guided Treatment in Gynaecological Cancer (Netherlands)
- NCT05646316 · Phase 3 — Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer (United States)
- NCT03422198 · Phase 3 — Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (United States)
- NCT05256225 · Phase 3 — Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (United States)
- NCT07198074 · Phase 3 — Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (United States)
- NCT04073706 · Phase 3 — Sentinel Node Biopsy in Endometrial Cancer (United States)
- NCT05559879 · Phase 1 / Phase 2 — Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma (United States)
Most-relevant first: trials that name Uterine Carcinosarcoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Questions to ask your oncologist
- I've read that Carboplatin has been studied in people for Uterine Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Ifosfamide has been studied in people for Uterine Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Paclitaxel has been studied in people for Uterine Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT05619913), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?